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Abstract
T cell directed HIV vaccines are based upon the induction of CD8+ T cell memory responses that would be effective in
inhibiting infection and subsequent replication of an infecting HIV-1 strain, a process that requires a match or near-match
between the epitope induced by vaccination and the infecting viral strain. We compared the frequency and specificity of
the CTL epitope responses elicited by the replication-defective Ad5 gag/pol/nef vaccine used in the Step trial with the
likelihood of encountering those epitopes among recently sequenced Clade B isolates of HIV-1. Among vaccinees with
detectable 15-mer peptide pool ELISpot responses, there was a median of four (one Gag, one Nef and two Pol) CD8
epitopes per vaccinee detected by 9-mer peptide ELISpot assay. Importantly, frequency analysis of the mapped epitopes
indicated that there was a significant skewing of the T cell response; variable epitopes were detected more frequently than
would be expected from an unbiased sampling of the vaccine sequences. Correspondingly, the most highly conserved
epitopes in Gag, Pol, and Nef (defined by presence in .80% of sequences currently in the Los Alamos database www.hiv.
lanl.gov) were detected at a lower frequency than unbiased sampling, similar to the frequency reported for responses to
natural infection, suggesting potential epitope masking of these responses. This may be a generic mechanism used by the
virus in both contexts to escape effective T cell immune surveillance. The disappointing results of the Step trial raise the bar
for future HIV vaccine candidates. This report highlights the bias towards less-conserved epitopes present in the same
vaccine used in the Step trial. Development of vaccine strategies that can elicit a greater breadth of responses, and towards
conserved regions of the genome in particular, are critical requirements for effective T-cell based vaccines against HIV-1.
Trial Registration: ClinicalTrials.gov NCT00849680, A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/
Pol/Nef Vaccine in Healthy Adults.
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Introduction
In principle, an effective HIV-1 vaccine designed to elicit
antiviral T cell immunity must direct those responses to T cell
epitopes likely to be present in the diverse population of circulating
viral strains. HIV-1 vaccines must either generate sufficiently broad
responses (multiple or cross-reactive responses) to compensate for
the extensive sequence variability among circulating HIV-1 strains,
or include highly-conserved epitopes likely to be present in a high
percentage of strains.
The HIV-1 genes represented in most candidate HIV vaccines
are typically full-length (or nearly full-length) genes derived from
natural isolates. These can be based on a natural strain specifically
selected to be relatively central to circulating strains in a given
population, to maximize the potential cross-reactivity [1], or by
selecting a natural sequence that maximizes coverage of potential
epitopes in a population of sequences [2,3]. Alternatively, one can
use synthetic sequences (e.g., consensus or inferred ancestral
[4,5,6]), or sets of sequences designed to optimize potential epitope
coverage as the basis for antigen design [2,7]. No studies have
determined experimentally whether conserved or variable epitopes
are preferentially recognized by the human T-cells after vaccination
with such immunogens and how this preference is related to the
outcome of clinical vaccine trials. Here, we present the results of an
extensive epitope mapping study from healthy volunteers who
received the same vaccine candidate as was subsequently admin-
istered to high-risk volunteers in a Phase IIB vaccine trial. The
epitope mapping is supplemented with theoretical analyses to
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20479evaluate the frequency and breadth of T cell response and evaluate
thedistributionofhighlyvs. poorlyconservedepitopes.This leadsto
conclusions for potential impact on vaccine efficacy and strategies
for future HIV vaccine development.
The Step trial, a test of concept study of a T cell based vaccine,
failed to reach its interim criteria for reduction in infection rates
and/or reduction of set point viremia, and further vaccinations
were suspended in September 2007 [8,9]. The vaccine candidate,
developed by Merck Research Laboratories, consisted of a
mixture of replication-defective Adenovirus type 5 constructs
containing the HIV-1 gag, pol, and nef genes which were inserted
into the E1 region of the Ad5 backbone. Gag and pol were selected
because of their relatively high conservation both interclade and
intraclade among all HIV gene products. Specifically, the gag
coding sequence was derived from the CAM-1 strain of HIV-1
(GenBank Locus BAA00992) [10], because its Gag amino acid
sequence most closely resembled the clade B consensus. The pol
construct included only the reverse transcriptase and integrase
gene products from IIIb, and nef from JRFL strains. All three
transgenes were optimized by using frequently utilized codons to
improve protein expression in mammalian cells [11]. The pol
transgene segment was inactivated by substituting alanine codons
for amino acids at enzymatically active sites [11,12,13,
14,15,16,17,18,19], and the nef transgene segment was inactivat-
ed through substitutions that prevent attachment to the
cytoplasmic membrane and retrotrafficking into endosomes
[17,20]. The vaccine was formulated as a 1:1:1 mixture of each
gene product and 3 separate doses of 10
10 viral particles of the
mixture were administered. The current study parallels the Step
trial; the vaccine was immunogenic in most individuals: .70% of
subjects who received the vaccine in the Step trial had detect-
able HIV-specific CD8+ T lymphocytes that were capable of
producing multiple cytokines, including IFN-c and TNF-a; these
responses were long-lasting, persisting for more than one year [9].
Despite these immune responses, the trial failed to meet its
endpoints for reduction in acquisition or reducing post-acquisi-
tion viral load. The reasons behind the lack of efficacy despite
being highly immunogenic remain unclear and are central to the
future development of an effective HIV vaccine.
We undertook an analysis of whether the T-cell epitope response
specificities elicited by vaccination were within conserved or variable
regions ofthe HIV proteins and whether the vaccineelicitedthe type
of T cell coverage likely to be effective after encountering the
diversity of HIV-1 circulating in the regions where the vaccine trial
was conducted. Specifically, we compared the overall conservation
levels of observed epitopes to 1) all the 9-mer CTL epitopes within
the three immunogens reported in the LANL database (‘‘known
epitopes’’) and 2) all the possible 9-mers (we defined as potential T
cell epitopes [PTEs]) within the three immunogens.
Results
T-cell epitope response breadth
We performed epitope mapping on 72 subjects who participated
in an earlier Phase I trial of the same vaccine utilized in the Step
study. Among them, 43 subjects were Ad5 seronegative and 29
were Ad5 seropositive at enrollment. The median age was 35; 85%
were Caucasian; 68% were male and 32% female. Their responses
to vaccination were similar if not higher in magnitude to those
enrolled in the Step trial. Details of the T cell and antibody
responses to the vaccine among these subjects have been described
[17]. Moreover, the subjects we analyzed were enrolled from
many US study sites in which the ensuing Step trial was
conducted. The incidence of HIV-1 acquisition in Step was
highest in the U.S [8]. As such, the epitope mapping data of these
samples from the earlier Phase I trial are of direct relevance to
immune responses seen in Step.
All vaccinees evaluated had positive responses to the Gag
15-mer peptide pool (72/72) and most also had responses to Nef
15-mer (68/72) and/or Pol 15-mer (56/72). Subsequent mapping
of the positive protein response using 9-mer minipools demon-
strated that CD8+ T cell epitopes were recognized across the
length of all three proteins with detectable responses to one or
more minipool per protein in 54% of Gag, 56% of Nef, and 79%
of Pol mapped individuals (Table 1). A relatively high number of
minipools per subject were detected in Pol; 20% of mapped
individuals had 4 or more detectable Pol minipool responses, while
only 3% of Gag and 3% of Nef had equally broad responses. The
median (and mean) of positive minipool responses per subject was
1 (1) for Gag, 1 (1) for Nef and 2 (3) for Pol. Although 15–22% of
minipools were recognized by only a single subject, more
minipools (23% in Gag, 50% in Nef and 42% in Pol) were
recognized by two or more subjects and response rates to some
individual minipools were relatively high, with 6–10 subjects
responding to a common minipool (Table S1). Deconvolution of
the individual 9-mer peptide response within the positive mini-
pools was completed for 228 minipools where response magnitude
and sample supply were sufficient. Individual 9-mer responses
were undetectable or below the positivity criteria in 61 of the
deconvoluted minipools. Responses to a single 9-mer epitope per
minipool were detected from 84% of the minipools. Responses to
two, or rarely three, 9-mer epitopes were detected from the
remaining 16% of minipools, but most were offset by just 1 or 2
amino acids with one dominant response; thus, these were likely
responses to the same epitope. A total of 105 distinct epitopes were
detected from the positive minipools, with 30, 20, and 55 in Gag,
Nef, and Pol, respectively (Table 2). The 9-mer peptides that
induced the most frequent responses ($5 subjects) were
Gag-RLRPGGKKK, Gag-ATLYCVHQK, Nef-RVRRTEPAA,
Nef-AVDLSHFLK and Pol-ITTESIVIW. Approximately half (57
of 105) of the gene-specific CTL responses detected in vaccinees
were directed at epitopes unique to an individual vaccinee (20 in
Gag, 9 in Nef, 28 in Pol).
T-cell epitope distribution along the immunogens
Vaccinated subjects with similar HLA types exhibited markedly
different epitope-specific responses. Despite individual variability
in the epitope specificity of the vaccine induced T cell response,
the location of the epitope responses after vaccination along the
protein sequence tracked well with the distribution of responses
reported in the literature after natural infection (Figure 1). There
was a very strong correlation between the number of epitopes that
Table 1. Breadth of response: Number of positive minipool
responses among Merck Ad5 gag/pol/nef vaccine responders.
No. positive pools (epitopes) Gag
a Pol Nef
0 pools 33 (46%) 12 (21%) 30 (44%)
1 pool 25 (35%) 15 (27%) 26 (38%)
2 pools 8 (11%) 9 (16%) 8 (12%)
3 pools 3 (4%) 9 (16%) 2 (3%)
$4 pools 3 (4%) 11 (20%) 2 (3%)
N mapped 72 56 68
aNumber (%) of vaccinees.
doi:10.1371/journal.pone.0020479.t001
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reported human HIV epitopes in the Los Alamos database
(Kendall’s rank correlation p,2610
216). This consistency suggests
that the localization of responses to the vaccine follows that of
initial infection, a desirable vaccine characteristic as the vaccine
elicited responses targeted to epitopes that are processed and
presented in infected human subjects. Given the relative length of
the Nef protein (216 amino acids, versus 850 in Pol and 500 in
Gag), there was a significantly greater density of responses to Nef
than to the other proteins (Chi Square test, p=0.03 comparing
Nef and Gag, p=0.007 comparing Nef and Pol).
Vaccine epitope coverage
We next performed a series of analyses to evaluate the likelihood
vaccinations would elicit responses to epitopes likely to be present
in circulating strains of HIV-1, a concept termed ‘‘coverage.’’ A
valid question for coverage analysis is whether the sequences from
Los Alamos database are representative of contemporary natural
infections. Frequency comparison of PTEs derived from contem-
porary, incident HIV infections with those from Los Alamos
database shows excellent correlation (Figure S1,p ,0.0001),
which supports the use of database sequences in this analysis. We
define vaccine coverage here to mean the fractions of viral
sequences in the target population containing $1, $2, $3,… of
the epitopes for a given vaccinee; the average of each of these
quantities over a sample of vaccinees provides the expected
vaccine coverage at a given degree (e.g., expected coverage by $3
epitopes). We note that for a genetically homogeneous viral
population, the expected coverage corresponds to response
breadth (e.g., fraction of vaccinees with $3 epitopes). Thus, the
Table 2. Frequency of distinct epitope responses among
Merck Ad5 gag/pol/nef vaccine responders.
No. vaccinees responding to the same epitope Gag Pol Nef
12 0 2 8 9
2–3 6 24 7
4–5 2 3 4
$62 0 0
Total distinct epitopes observed 30 55 20
doi:10.1371/journal.pone.0020479.t002
Figure 1. Tracking the frequency of defined epitopes to the vaccine proteins and the database of responses to natural infection
and across the vaccine proteins. The blue histograms mark the number of epitopes in the database that span each amino acid position in the
protein. The yellow bars track the same number for the 72 vaccinees. The bright blue line tracks the level of coverage the vaccine provides of B clade
sequences in the database. The sharp dips are either a consequence of the natural strain carrying very unusual amino acids, or amino acids
engineered into the protein enhance the safety of the vaccine. The red line, in contrast, is a ‘‘neutral’’ measure of the overall diversity of each 9-mer,
not relative to any one strain; it tracks the frequency of the most common 9-mer, for each 9-mer. Frequency of 9-mer PTEs is calculated from Los
Alamos database sequences to reflect contemporary natural infections as supported by the high correlation between them (Figure S1).
doi:10.1371/journal.pone.0020479.g001
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response and the pattern of population frequencies for the sets of
epitopes among vaccinees. Direct estimates of expected vaccine
coverage are presented in Table 3. The average vaccinee would
cover with $1 epitopes in any gene 57% of a clade B viral
population and this coverage decreases to 35% for $2 epitopes
and 20% with $3 epitopes.
Our analysis also revealed a low frequency of recognized
epitopes in the circulating strains that is not obvious from protein
similarity (or distance) (Table S2). For example, the Nef insert has
an average protein similarity of 78% to subtype B strains while the
average epitope frequency in the same viruses is only 9%. This is a
direct consequence of CD8 epitopes typically being around 9
amino acids long; if 22% of the positions vary between two strains
it is correspondingly highly likely that one or more of the 9
positions in the CD8 epitope will vary.
Variable epitopes are preferentially recognized
To augment this analysis of expected vaccine coverage, we
explicitly examined epitope-specific coverage by comparing the
overall conservation levels of observed epitopes to 1) known
epitopes within the three immunognes and 2) all the 9-mers within
the three immunogens in subtype B strains (Figure 2). The
frequencies of the mapped epitopes among vaccinees to each of
the three proteins, Gag, Pol, and Nef are significantly lower than
those of the known epitopes (Kolmogorov-Smirnov test; p,0.001
Gag, p,0.001 Nef, p,0.01 Pol), although this result is likely due
to an artifact of the over-representation of conserved elements in
peptides used to detect CTL responses (the ‘‘founder effect’’)
[21,22]. This effect is particularly pronounced for the Nef protein.
Recognized epitope frequencies to the three HIV proteins after
vaccination were also lower than 9-mer PTEs in the immunogens
(Kolmogorov-Smirnov test; p,0.05 Gag, p,0.05 Nef, p,0.01
Pol), suggesting a preference for recognition of variable epitopes.
Although statistically significant for Gag and Pol, the magnitude of
these differences is relatively modest (Figure 2). Nonetheless,
detailed examination of the differences for Gag and Pol suggest
that relatively variable epitopes (with frequency 0.1–0.4) were
over-represented in the observed epitopes (Figure 2, Table 4)
and highly conserved epitopes (frequency .0.8) in Gag and Pol
were under-represented. A similar difference in the distribution of
recognition frequencies of highly conserved versus less conserved
potential epitopes after wild-type infection with HIV-1 was noted
based on the Los Alamos Immunology database (Wilcoxon rank
test p=0.0006), suggesting some form of ‘‘antigenic masking’’ of
these regions may occur.
Compared to other subtype B viral strains, the Merck sequences
perform better as vaccine sequences than most subtype B, due to
being selected to be relatively central relative to circulating strains
(Figure 3). This mitigates against the bias towards less-conserved
epitopes. Comparingagainst the predicted overlap with theepitopes
directly identified in the 9-mer epitope mapping data, these
opposing effects nearly cancel so that the mean conservation score
ofa mappedepitope isnearlyequal tothetypicalclade B epitope for
Gag. That is, the bias for less-conserved epitopes is cancelled by the
highly-conserved Gag CAM1 sequence. The same opposition holds
for Pol and Nef, except that the net effect is a mean epitope
conservation of less than the typical clade B epitope. For Pol and
Nef, there is a 3–5% and 11–6% respective additional risk of a
mismatch, depending upon the particular assumption that 8 or 9
amino acids in a 9-mer must match (Table 5).
Optimal T-cell epitope coverage
We then performed a simple statistical analysis of the T cell
breadth required to achieve a high probability that vaccine elicited
epitope responses will be of the type that match the epitope
frequency in circulating strains in a population. We plotted the
individual-level vaccine coverage probabilities versus breadth of
response (number of defined epitopes) and fit non-linear quantile
regression models to the resulting scatterplot in order to project the
response breadth required for different levels of expected vaccine
coverage (Figure 4). The results of these analyses suggest that a T
cell based vaccine containing gag/pol/nef would require four or
more epitope responses to be elicited in order to expect 90%
coverage by 1 or more epitopes. As epitope escape early in
infection has been reported, it is desirable to have multiple
epitopes present; our analysis indicates that two or more epitopes
at 90% coverage need 6 or more epitopes to be recognized, and
three or more epitopes need 8 to 9 epitopes. This prediction
assumes the same degree of conservation of epitopes as observed in
the current data. However, if responses to more highly conserved
epitopes are elicited by vaccination, the number of epitopes
required to achieve coverage may be markedly reduced.
Development of a more detailed predictive model of vaccine
coverage as a function of both breadth and epitope-level frequency
would be useful for guiding future insert designs and for assessment
of coverage by future candidate vaccines. The above analysis of
epitope coverage implicitly assumes that T-cell epitopes have equal
efficacy. For example, recent studies suggest that epitopes
restricted by some HLA alleles are more likely to be associated
with reduced viral load than other epitopes [23,24].
Discussion
Our analyses provide an important series of observations about
the outcome of the Step trial and future immunogen design. It is
clear that while immunogenic in most individuals, the Merck gag/
pol/nef vaccine tended to elicit responses to fewer highly
conserved epitopes and more less-conserved epitopes than would
be predicted from the vaccine sequences alone. An interesting
question is raised as to how generic this bias towards less-
conserved epitopes may be. The mechanism for these observations
are unclear; potential explanations include that such highly
conserved but relatively immunologically silent regions could be
the consequence of retroviruses evolving to evade epitope
processing in regions where mutations have a very high fitness
cost, or could be due to very conserved domains also being
conserved in HERVs (Human Endogenous Retroviruses), causing
such regions to be seen as ‘‘self’’. To our knowledge, this is the first
study to analyze this question in the context of high-resolution
epitope mapping with a high number of patients and a clinical
HIV-1 candidate. The extent to which the bias may be related to
Table 3. Expected vaccine coverage: Fraction of target viral
sequences covered by epitopes among recipients of Merck
Ad5 gag/pol/nef vaccine.
No. Epitopes Any Gene
a Gag Pol Nef
0 epitopes 17% 16% 10% 35%
1 epitope 22% 25% 21% 10%
2 epitopes 15% 5% 11% 1%
3 epitopes 10% 1% 5% 0%
$4 epitopes 10% 0% 11% 0%
aExpected % of viral population covered.
doi:10.1371/journal.pone.0020479.t003
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vaccination vs. natural infection is an important question to guide
further vaccine development.
We consider the implications of these results upon vaccine
efficacy in general, and the Step trial (which employed the same
vaccine as studied here) in particular. First, patients became
infected in both placebo and vaccine arms of the Step trial.
Mutation of HIV-1 to escape effective T cell recognition has been
frequently observed in humans and non-human primates. The
probability of escape is a complicated function of viral load,
conservation at the amino acid and nucleotide level, and HLA
association. Analyses of these complex interactions through HIV-1
sequencing of infected patients are underway. We merely point
here out that eliciting responses to highly-conserved epitopes
would, in general, be expected to reduce the overall frequency of
viral escape. Second, the number of persons who become infected
may be greater for a T cell vaccine that elicits responses to less-
conserved epitopes. Less conserved epitopes are less likely to be
shared between vaccine and infection virus strains. Assuming a
worst-case complete immunodominance model such that only a
single epitope amongst Gag, Pol, or Nef is recognized (despite our
data to the contrary in Table 3), and if failure to match this single
Figure 2. Comparison of cumulative (upper) and density (lower) distributions of PTE, known and defined epitope in subtype B
strains. The yellow shaded area indicates the cumulative and density distributions of PTEs from vaccine inserts. The green and red lines are the
distribution curves for defined epitope and known epitopes respectively. The relative variable epitopes are enriched and highly conserved epitopes
are underrepresented in this study. Known epitopes in LANL are overrepresented as expected.
doi:10.1371/journal.pone.0020479.g002
Table 4. Comparison of PTE and defined epitope with different conservation level.
Conservation level Gag Pol Nef
Epitope PTE Epitope PTE Epitope PTE
Highly variable(0-) 1 (2%) 43 (9%) 6 (6%) 132 (16%) 22 (50%) 81 (39%)
Relatively variable(0.1-) 18 (34%) 62 (13%) 21 (21%) 64 (8%) 15 (34%) 63 (30%)
Relatively conserved(0.4-) 24 (45%) 228 (46%) 45 (46%) 286 (34%) 7 (16%) 61 (29%)
Highly conserved(0.8-) 10 (19%) 159 (32%) 26 (27%) 360 (43%) 0 (0%) 3 (1%)
Total 53 (100%) 492 (100%) 98 (100%) 842 (100%) 44 (100%) 208 (100%)
doi:10.1371/journal.pone.0020479.t004
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on predicted infection rates?
The experiments and analyses are based upon epitopes of only 9
amino acids in length, thereby omitting CD8 epitopes of 8, 10 or
11 amino acids. In this and subsequent analyses, we may
undercount these less frequent non-9-mer epitopes. For example,
epitope mapping of select vaccinees with B57/B58 alleles and B27
alleles has shown that key 10 mer Gag epitopes such as TW10 and
KK10, respectively, can be detected with peptides 10 or 15 amino
acids in length but not with 9-mer peptides. Undercounting of
vaccine-induced epitopes may also occur due to the ELISpot assay
method. Positivity criteria were established to limit false positive
Figure 3. Histograms of all possible N-mer conservation scores for Gag (a) N=8/9, (b) N=9/9; Pol (c) N=8/9, (d) N=9/9; and Nef (e)
N=8/9, (f) N=9/9. Solid vertical lines show the mean conservation of the Merck vaccine sequence vs. all others in the distribution. Dashed vertical
lines show the mean conservation score of the ELISpot response.
doi:10.1371/journal.pone.0020479.g003
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missed at these cut-offs, particularly as responses are narrowed
down to the single peptide level. A second issue may complicate
the interpretation of the results is TCR recognition degeneracy; A
study of 9-mer ELISpot mapping data and multi-isolate
sequencing from HIV-infected individuals [25] indicated that
one mismatch per 9-mer can still be cross-reactive (although this is
subject to HLA restriction). However, even with this cross-
reactivity suggested by experiment, the requirement that multiple
amino acids match elsewhere in the 9-mer leads to a nonlinear
relationship between the number of 9-mers matching and the
number of amino acids [25]. Specifically, as homologies move
from more to less conserved, epitope overlap will fall off faster than
a traditional sequence/protein homology score would suggest, and
this disparity is apparent in actual epitope mapping data. This is a
further consideration in the types of inserts that should be designed
for candidate HIV-1 vaccines [2,26,27]. Another finding worth
noting from this study is that vaccinated subjects with similar HLA
Table 5. Comparison of 9-mer overlap of vaccine sequences, mapped epitopes with clade B sequences.
Gene N=8/9 amino acid identity expectation value N=9/9 amino acid identity expectation value
Intra-Clade B vaccine sequence mapped 9-mers Intra-Clade B vaccine sequence mapped 9-mers
Gag 81% 87% 82% 49% 59% 49%
Nef 55% 60% 44% 25% 28% 19%
Pol 92% 93% 89% 64% 70% 59%
doi:10.1371/journal.pone.0020479.t005
Figure 4. Coverage by $1, $2 and $3 epitopes of a Subtype B viral population vs response breadth (number of epitopes). The
points are subject-specific estimates of % viral population (Subtype B) covered by $1, $2 and $3 epitopes versus subject-specific breadth (epitope
number) on log scale. The data fit well with both quadratic and cubic regression.
doi:10.1371/journal.pone.0020479.g004
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which emphasizes the importance of other factors other than
HLA restriction in immune recognition. Indeed, we observed a
strikingly different response pattern on the vaccine participants of
STEP trial (data not shown).
Our analysis illustrates the need to explore several new avenues
for eliciting effective T cell-based immunity for HIV-1 vaccines.
One approach to achieving the immune focusing required to elicit
responses to conserved regions of the genome is to construct
artificial immunogens by linking together highly-conserved
epitopes or regions [28]; however, such strategies have proved
poorly immunogenic in human phase I immunogenicity trials
[29,30]. Alternatively, one could attempt to develop immunogens
with variable regions masked against immune recognition. With
either of these approaches, a vaccine that stimulated responses
primarily to these most-conserved epitopes may be less effective if
these epitopes are infrequently presented in natural infection.
Alternatively, algorithms could be designed to choose optimal
natural sequences, or sets of natural sequences, to maximize
epitope breadth and conservation. These could be extended to
heterologous inserts for prime and boost vaccination to succes-
sively boost the conserved epitope determinants. This strategy,
especially if utilized with one or more viral vectors, may generate
responses focused on more highly conserved epitopes with each
successive inoculation, while shared conserved epitopes would
always be presented in a natural protein context.
The Step trial has raised the minimum threshold for the level of
T cell immunity that must be elicited in human subjects for an
effective outcome. The importance of a high responder frequency
and the magnitude, quality, and breadth of response are well
appreciated. The result presented here is that both HIV infected
subjects and healthy volunteers immunized with the same vaccine
as in the Step trial exhibited a response biased towards less-
conserved epitopes. Developing an effective T-cell based vaccine
as part of an overall HIV-1 vaccine will require eliciting robust
responses to well-conserved epitopes. Overcoming this bias will
require both an improved understanding of HIV and its
interaction with the presentation and processing machinery,
probing the underlying causes for potential bias towards less-
conserved epitopes, and the refinement of computational design
strategies to overcome this bias and refocus the immune response
on a broad set of highly conserved epitopes.
Materials and Methods
Epitope mapping
Epitope mapping after vaccination was performed on a study
cohort based on previously determined positive ELISpot responses
to complete 15-mer peptide pools for each protein [31]. We
utilized a modified IFN-c ELISpot assay using peptide minipools
matching the vaccine immunogen sequences to determine the
breadth of epitope response to the vaccine. Each pool contained
eight overlapping 9-amino-acid peptides spanning a 16-amino-
acid region. Where sample was sufficient, positive minipool
responses were resolved by subsequent ELISpot assay using the
individual 9-mer peptides in the responding minipool. Cut-offs to
establish a 5% false-positive rate in the individual 9-mer assays
were experimentally determined to be $4x mock and $80 (gag),
55(nef), 70 (pol pool-1) and 80 (pol pool-2) spots/10
6 PBMC.
Epitope frequency in circulating strains
130 (one per patient), recently-isolated HIV-1 subtype B
genome sequences were obtained from Los Alamos HIV Sequence
Database (http://www.hiv.lanl.gov). Intact Gag, Pol and Nef
proteins sequences were derived from the corresponding coding
regions of the genomes. Frequencies of reactive, known and
potential T-cell epitopes were calculated according to their
occurrence in the viral sequences. Experimentally defined known
HIV CTL epitopes were obtained from the same source.
Conservation of epitopes relative to clade B circulating
strains
Amino acid sequences with unique patient identifiers and
designated as subtype B were downloaded from the Los Alamos
HIV Sequence Database in August 2009. Due to the design of the
Step trial, clade B sequences are the vaccine sequences and
expected viral challenge sequences. Sequences were cleaned by
removal of gaps and trailing stop codons and replacement of
intermediate stop codons and unknown amino acids by a standard
character (‘X’). To avoid potential bias due to the submission of
partial sequences to the LANL database, only complete or near-
complete sequences were included in the analysis. Gag sequences
were required to have 500620 amino acids, Pol 850620 amino
acids, and Nef, 210 220, 210+14 amino acids. For Gag, 1506
sequences from 461 patients were used; Nef, 5177 sequences from
784 patients; and Pol (RT through IN), 741 sequences from 236
patients.
Sequences were compared as described previously [25]. Briefly,
amino acid sequences were compared pairwise by 9-mer amino
acid identity, according to two rules. For 9/9: all 9 amino acids
much match. For 8/9: 8 out of 9 amino acids much match (the
position of mismatch within the 9-mer is irrelevant). Up to one
unknown comparison is allowed without penalty. That is, a single
X in either N-mer is considered to be identical to the amino acid at
the same position in the other N-mer. Calculations were patient-
normalized (all patients contribute equally to the analyses,
regardless of the number of sequences they contribute to the
sequence database).
Ethics statement
The data presented here are derived from a safety and
immunogenicity vaccine study in HIV-seronegative adults [17].
Participants were followed for up to 78 weeks for immunoge-
nicity and 260 weeks for safety. The protocol was approved by
review boards at participating centers (V520-016 study group),
and written informed consent was obtained from all participants.
Ongoing risk assessments and preventive counseling were
offered to participants during the trial. Further details on
enrollment and exclusion criteria have been previously published
[17]. For the current study, participant-specific information was
stripped from the data and identifiers were re-randomized
before analysis.
Supporting Information
Figure S1 Comparison of PTE frequency of Los Alamos subtype
B Env with those of recently isolated subtype B Env from Chavi
study. Frequencies of PTEs are highly correlated (p,0.0001)
between the sequence sets.
(TIF)
Table S1 Positive minipools and 9-mer epitopes indentified from
Merck Ad5 gag/pol/nef vaccine responders
(DOC)
Table S2 Median protein similarity and reactive epitope
frequency in subtype B and C strains
(DOC)
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